Navigation Links
Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Date:7/17/2008

but to evaluate such data in a blinded and centrally reviewed manner in order to be able to use the PFS data for additional labeling consideration. As the trial is currently designed, PFS data is being collected as an exploratory secondary endpoint. New regulatory submissions can include secondary endpoint data to support labeling claims for registration purposes if the data are collected in an acceptable manner. In some cases, secondary endpoint data can also provide early insight into patient benefit from an ongoing Phase III trial.

A recent article published in Neuro-Oncology (Lamborn et al, 2008) examined six-month progression free survival as a predictor of overall survival in glioma patients. The article included data from 597 adult patients with recurrent high-grade gliomas that enrolled in Phase II trial protocols collected by the North American Brain Tumor Consortium between 1998 and 2002. The study concluded that progression status at 9, 18, and 26 weeks were strong predictors of survival and that progression free survival is a valid endpoint for trials of therapies for recurrent malignant glioma.

Bradmer's PFS analysis is based on 19 GBM patients in two recent single-arm Phase II trials of Neuradiab with a targeted dose of 44 Gy delivered as an adjunct to the current standard of care consisting of surgery, temozolomide and external radiation therapy (study 01128; n = 21 (Reardon et al., J Neuro-Oncology, Doc. D06-00199, February 20, 2008) (http://neuro-oncology.dukejournals.org) (DOI:10.1215/15228517-2007-053) and study 05018; n = 5).

In addition, Bradmer has reviewed the existing external GBM literature, and in nine of the eleven studies published between 2003 and 2008 by outside parties that the Company analyzed, progression free survival ranged from 4 to 10 months, with two other studies achieving 13 month and 17 month PFS results. The results from the external stu
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Reports Progress on Its AIDS Vaccine Technology
2. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
3. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
4. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
7. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
8. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
9. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
10. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
11. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Boston Scientific Corporation (NYSE: ... 2015 Annual Healthcare Conference on March 10 in ... Brennan , executive vice president and chief financial officer, ... will participate in a 25-minute question and answer session ... 1:05 p.m. ET. Following a 5-minute break, a question ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
(Date:2/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... results for its first quarter ended December 31, 2014. ... 31, 2014, revenue was $1,336,685. Operating expenses were $1,063,393. ... per share.  Covalon,s President and CEO, ... with the significant progress we have made over the ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... to Timeline for Second Pivotal Phase 3 Trial ... Life,Sciences Holdings, Inc. , today announced the confirmation ... of two,pivotal Phase 3 clinical trials designed to ... once-a-day antibiotic, for,the treatment of community acquired pneumonia ...
... 2, 2007-Women with at least three sites of,cellular atypia ... average women to develop breast cancer, according to findings,of ... with atypical,hyperplasia. The findings are published in the July ... studies have shown that atypical hyperplasia,(also called atypia) in ...
Cached Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 2Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 3
(Date:2/27/2015)... February 27, 2015 Dr. Christopher Saunders, ... Augmentation Special at his Chadds Ford, Pa., location. The ... 1, 2015, and will be priced at $3,950 with ... silicone implants, it will include more than $3,000 in ... worth of free Dysport. , Space is very limited, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The Lymphoma ... devoted exclusively to funding innovative lymphoma research and serving ... programs, outreach initiatives and patient services – is continuing ... community, returning to the greater Miami area to host ... Country Club in Miami Beach on Thursday, March 26, ...
(Date:2/27/2015)... Over 440,000 patients die annually as a result of preventable ... airplanes crashing each day. Now more than ever before, hospitals ... do all they can to stay safe. , Through ... Surgeon General, discusses the importance of safer hospitals. “It’s incumbent ... issues to ensure that all our patients are in the ...
(Date:2/27/2015)... Muscular Dystrophy Association research grantee ... Duke University, recently announced a potentially game-changing advance ... with Duchenne muscular dystrophy (DMD). The results were ... will discuss their implications at MDA's 2015 Scientific ... D.C. , Background: Gersbach and team are ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 Over 440,000 ... harm. The time is now to educate readers on how ... condition. This campaign will serve as a guide to educate ... keep themselves and their loved ones safe with tips on ... Richard Carmona graces the cover of the print publication. He ...
Breaking Medicine News(10 mins):Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 3Health News:Lymphoma Research Foundation Returns to Miami Beach For Exclusive Swirl Wine Tasting Event 2Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2Health News:Safe and Sound: Improving Patient Outcomes through Mediaplanet’s “Patient Safety” Campaign 2
... of Procedure and Improved Clinical ... ... Corporation (Nasdaq: SPNC ) today announced the presentation,of results from ... at the nineteenth annual Transcatheter,Cardiovascular Therapeutics (TCT) scientific symposium in Washington, ...
... Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based,medical device company ... ultrasound tumor,therapy systems, today announced the following investor events: Event ... ... Location UBS China Life Sciences Conference ...
... uranium (DU) oxide aerosols are recognised as a distinct human ... in part for illness in both military and civilian populations ... Professor Randall R Parrish will be giving this message to ... at the Colorado Convention Center in Denver on 28 October ...
... Providing 10,000 Meals per Day, Emotional & Spiritual Care, ... surrounding the 2003 southern California wildfires only,weeks ago, The ... support to relief workers and survivors in the wake ... canteen units have been,deployed throughout the area and six ...
... Since wildfires began raging across,San Diego County ... 166 patients,affected by the blazes at its hospital-based ... to arrive at Scripps, emergency departments with a,wide ... as respiratory,distress, fall-related injuries, chest pain, hypertension, sinus,infections, ...
... Oct. 23 Pharmaceutical Research and,Manufacturers of America ... statement regarding the California wildfires: "Californians who ... and who,are uninsured or underinsured -- should know ... available through the Partnership for,Prescription Assistance. The PPA, ...
Cached Medicine News:Health News:Spectranetics Announces Clinical Data From Cello Trial 2Health News:Spectranetics Announces Clinical Data From Cello Trial 3Health News:Spectranetics Announces Clinical Data From Cello Trial 4Health News:China Medical Technologies to Participate in Investor Events in November 2Health News:Contamination from depleted uranium found in urine 20 years later 2Health News:The Salvation Army Responds to Immediate Needs of Survivors and Relief Workers in Southern California Wildfires 2Health News:The Salvation Army Responds to Immediate Needs of Survivors and Relief Workers in Southern California Wildfires 3Health News:Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County 2Health News:Help for California Fire Evacuees Possible Through Partnership for Prescription Assistance 2
This ultra micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume....
... The economical way to order tips. ... of 1000 tips). Also available in easy-to-open, ... pack. Bulk Packs are sealed with a ... for quick access to Gilsons Diamond Tips. ...
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Inquire...
Medicine Products: